← FDA DRUG APPROVALS

FDA ANDA · ANDA076958

LOSARTAN POTASSIUM

Sponsor: TEVA

APPLICATION
ANDA076958
TYPE
ANDA
ORIGINAL APPROVAL
2010-04-06
LATEST ACTION
2026-05-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LOSARTAN POTASSIUMDiscontinued
LOSARTAN POTASSIUM 50MG · TABLET · ORAL
LOSARTAN POTASSIUMDiscontinued
LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUMDiscontinued
LOSARTAN POTASSIUM 25MG · TABLET · ORAL

Approval history

2026-05-07Labeling · Supplement 19 · standardAP
2022-06-30Labeling · Supplement 17 · standardAP
2016-06-09Labeling · Supplement 14 · standardAP
2015-10-22Labeling · Supplement 12 · standardAP
2014-09-21Labeling · Supplement 11 · standardAP
2014-09-21Labeling · Supplement 9 · standardAP
2012-12-19Labeling · Supplement 8 · standardAP
2012-12-19Labeling · Supplement 7AP
2011-01-31Labeling · Supplement 6AP
2011-01-31Labeling · Supplement 4AP
2010-04-06OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →